A rotary tablet line handling amoscanate begins with the recognition that direct compression of the micronised API is not a plausible default when the drug substance is cohesive and poorly water-soluble. The API is first characterised for particle size distribution by laser diffraction under ISO 13320:2020, and the D50 target is tied to dissolution response rather than set arbitrarily. If dissolution is surface-area dependent, micronisation below 25 µm is implemented and the resulting agglomerates are pre-blended with a hydrophobic-free carrier. A wet granulation route is selected after a binder screen: microcrystalline cellulose PH-102 and lactose monohydrate are blended with the API to a working ratio of 1:3 to 1:5 on a weight basis after assay adjustment. Povidone K29/32 is added as an aqueous solution at 3–5% w/w of the dry granulate mass in a high-shear mixer, and the wet mass is passed through a 1.5 mm sieve before drying in a fluid-bed dryer at an inlet temperature not exceeding 60 °C. Drying is stopped when loss on drying reaches 2–4% by Ph. Eur. 2.2.32. The dried granules are lubricated with magnesium stearate at 0.5–1.0% w/w; lubrication time is held below 5 min because over-lubrication reduces tablet hardness and delays disintegration. Compression is performed on a rotary press with D or B tooling and a paddle feeder to maintain die fill. Tablet hardness is targeted between 5 kP and 8 kP, friability is kept below 1% under Ph. Eur. 2.9.7 or USP <1216>, and weight variation is monitored according to Ph. Eur. 2.9.5 or USP <905>. If film coating is required, aqueous coating at 3% weight gain is applied with a pan coater at a bed temperature of 40–45 °C. The terminal finished product is a film-coated tablet packed in HDPE bottles or aluminium-PVC blisters, released by dissolution testing using USP <711> or Ph. Eur. 2.9.3 with a medium selected by discriminating dissolution development. The ratio of API to excipients is recalculated from the actual assay for every batch because dose and tablet mass vary by target species and body weight band.

What Limits Terminal Sterilisation of Amoscanate Parenteral Solutions?

Amoscanate parenteral solutions present a conflict between the need for complete solubilisation and the risk of thermal degradation during terminal sterilisation. The molecule is screened in propylene glycol and PEG 400 co-solvent systems at 20–60% v/v; each formulation is challenged in a bench-top autoclave at 121 °C for 15 min, and the batch is moved to aseptic filtration if assay loss exceeds 2% or total impurities exceed 0.5%. A representative 100 mg/mL injection bulk may contain 40% v/v propylene glycol, 20% v/v PEG 400, and water for injections to volume, but the exact ratio is adjusted after solubility equilibration at 2–8 °C to prevent crystallisation during storage. The pH is not fixed by convention; forced degradation at 70 °C/75% RH for 7 days defines the stable pH range. Terminal sterilisation by steam is acceptable only when degradation kinetics show acceptable impurity profiles; otherwise the solution is passed through a 0.45 µm prefilter and a 0.22 µm PVDF membrane filter under aseptic conditions. When steam sterilisation is used, an F0 value of 8–12 min is targeted and the co-solvent system is evaluated for pH shift, vapour pressure, and filter compatibility before registration. The filtered bulk is filled into Type I borosilicate glass vials under a nitrogen headspace to limit oxidative degradation. Release testing includes sterility by Ph. Eur. 2.6.1 or USP <71>, bacterial endotoxins by USP <85> or Ph. Eur. 2.6.14, particulate matter by USP <788> or Ph. Eur. 2.9.19, and container closure integrity under Ph. Eur. 3.2.9. VICH GL18 residual solvent limits are applied when propylene glycol or PEG 400 is used above compendial thresholds. The terminal finished product is a parenteral injection in amber glass vials, and the label must state the co-solvent concentration because field dilution with aqueous solutions can precipitate the API. Published data for this specific configuration is limited, so forced degradation and factorial design studies are used to establish the registered control space.

Powder-filled hard capsules are manufactured when dose flexibility over a broad body weight range is required and the API is not exposed to granulation water. The process begins with a geometric dilution of amoscanate with a portion of lactose monohydrate at a 1:1 ratio to break loose agglomerates, then the pre-blend is transferred to a tumble blender with the remaining lactose, pregelatinized starch, crospovidone, and colloidal silicon dioxide. For a representative 25 mg capsule with a fill weight of 250 mg, the API content is 10% w/w; crospovidone is limited to 2–5% w/w, sodium stearyl fumarate to 1% w/w, and colloidal silicon dioxide to 0.5% w/w. These levels are not fixed specifications but are varied during blend uniformity studies under Ph. Eur. 2.9.40 or USP <905>. Encapsulation is performed on a dosator or tamping-pin machine with in-process weight control; tamping-pin machines require a flowable blend, so the blend is released only when the Carr index is below 25 and the Hausner ratio is below 1.20. If the sorption isotherm shows more than 2% moisture uptake at 60% RH, hard gelatin capsules are replaced with HPMC shells to prevent crosslinking and delayed dissolution. The terminal product is packaged in HDPE bottles with desiccant, and dissolution is evaluated using USP <711> or Ph. Eur. 2.9.3 after discriminating medium development. Batch-to-batch variance is highest at the lubrication stage; extended mixing times above 10 min with sodium stearyl fumarate can reduce drug release because hydrophobic films form on the API surface, so mixing time is validated at the upper limit rather than only at the optimum.

Oral Dusting Powder Homogeneity Limits in Low-Shear Blenders

Amoscanate oral powders are formulated for top-dressing on feed or for user dilution; the critical manufacturing parameter is homogeneity when the final concentration is low. For a 10% w/w stock powder, 100 g amoscanate is dispersed stepwise into 900 g lactose monohydrate or spray-dried sorbitol. The first dilution step uses a 1:1 API-carrier trituration passed through a 300 µm hand screen; the second step uses a 1:3 ratio in a low-shear ribbon blender at 20–30 rpm for 10–15 min. Blend uniformity is measured by taking 10–30 sampling points with a thief sampler; acceptance requires an assay relative standard deviation below 5% for the 10% w/w powder, and the limit is tightened further for lower-concentration field dilutions. Particle size mismatch between the micronised active and the carrier is the main segregation risk: if the carrier has a D50 above 250 µm and the API D50 is below 25 µm, electrostatic adhesion may improve homogeneity but reduce bulk flow. Dust control is achieved by adding 0.5–1% w/w medium-chain triglycerides or light mineral oil after the first dilution step; this addition must be validated because it changes powder flow and sifting behaviour. The finished product is filled into multi-laminate foil sachets or HDPE jars under RH-controlled conditions. Release testing includes sieve analysis by Ph. Eur. 2.9.38 or USP <786>, loss on drying by Ph. Eur. 2.2.32, and bulk and tapped density by USP <616>. When the oral powder is authorised as a veterinary medicinal product, the dossier follows Regulation (EU) 2019/6; if it is used in medicated feeding stuffs, feed business operators must also validate mixing and carryover under Regulation (EC) 183/2005 and Codex CAC/RCP 54-2004.

Oral granules are produced when a solution or a simple powder cannot deliver field dosing accuracy with an oral syringe or when taste masking of the API is required. Amoscanate is granulated in a fluid-bed top-spray system using an aqueous or hydroalcoholic binder solution of povidone K90 at 3–6% w/w of the dry granulate mass. The powder bed consists of the API blended with mannitol and low-substituted hydroxypropyl cellulose; a representative batch for 100 mg/g granules contains 10% w/w amoscanate, 55% mannitol, 25% microcrystalline cellulose, 6% povidone K90, 3% croscarmellose sodium, and 1% fumed silica. The granulation endpoint is controlled by droplet size, inlet temperature, and spray rate rather than by time alone; inlet temperature is maintained below 60 °C to avoid excessive drying that produces friable agglomerates. Drying continues until loss on drying by Ph. Eur. 2.2.32 falls within 2–4%, and the granules are then milled through a 1.0 mm screen to remove oversized material. Flowability is measured by Ph. Eur. 2.9.36 or USP <1174>; the release acceptance is set from the field delivery device, typically an oral dosing syringe. The terminal finished product is packed in unit-dose sachets or HDPE tubes, and the package includes a desiccant when moisture uptake studies show significant water sorption. Blend uniformity after granulation is confirmed by Ph. Eur. 2.9.40 or USP <905>, and dissolution is tested using USP <711> or Ph. Eur. 2.9.3 if the granules are intended to be swallowed rather than dispersed in water. Batch-to-batch variance is greatest at the binder addition step because uneven droplet distribution generates variable granule density and drug distribution; this is controlled by mapping spray nozzle airflow and atomisation pressure for each batch size.

Premix Homogeneity Fails When Carrier and API Particle Size Distributions Diverge by More Than 200 µm

Medicated premixes containing amoscanate are manufactured at 1% to 5% w/w active concentration in a mineral or vegetable carrier. The API is first geometrically diluted with calcium carbonate or wheat middlings in a paddle mixer, then transferred to a double-ribbon mixer for 15–20 min. Homogeneity is confirmed by sampling at 10 locations across the mixer; a coefficient of variation below 5% is expected for a 5% premix, while a 1% premix may require a multi-stage dilution sequence to reach the same CV. Particle size mismatch is the controlling risk: if the API D50 is below 20 µm and the carrier D50 exceeds 250 µm, the difference is greater than 200 µm and segregation becomes likely during transfer, packaging, and pneumatic conveying. Electrostatic adhesion of the API to the carrier may improve initial homogeneity but reduces flowability and can cause bridging in silos. In the feed mill, the premix is diluted with ground corn or soybean meal; carryover is managed by sequencing a non-medicated feed batch after the medicated batch and flushing the line with 25–50 kg of ground corn before the next non-target species feed is manufactured. The terminal product is a 20 kg multi-wall paper bag with an inner polyethylene liner or a 25 kg bag. Regulatory controls include Regulation (EU) 2019/6 for the veterinary medicinal product premix and Regulation (EC) 183/2005 for feed hygiene; carryover validation is documented using Codex CAC/RCP 54-2004. If amoscanate is authorised only for a restricted species, the mill must either use a dedicated line or validate cleaning with analytical verification of API carryover below the carryover limit specified in the marketing authorisation.

Drinking-water and oral drench solutions present a clarity and stability challenge for amoscanate because the API must remain dissolved in field water that may contain calcium and magnesium carbonate. The formulation is screened in co-solvent systems of propylene glycol, ethanol, and water at concentrations between 5 mg/mL and 20 mg/mL. A solubility reserve of at least 20% above the label concentration is required at the lowest claimed storage temperature, because dilution into hard water with combined Ca²⁺ and Mg²⁺ above 300 mg/L can depress the cloud point and cause precipitation. The manufacturing process uses a jacketed stainless-steel vessel with a high-shear disperser; the API is pre-slurried in propylene glycol before the aqueous phase is added at 20–25 °C to avoid local supersaturation. pH adjustment is limited to cases where forced degradation data show acid-base instability; unnecessary buffer addition is avoided because buffer salts can reduce the cloud point and accelerate particle formation in hard water. The terminal finished product is filled into HDPE or PET bottles under nitrogen to limit oxidative degradation, and the package may include a dosing pump or graduated dosing chamber. Clarity is assessed by visual inspection using a Tyndall beam, and particle formation is monitored by sub-visible particulate matter testing where the product is intended for parenteral use. For oral solutions, the marketing authorisation specification defines clarity and particulate limits; if the product is intended for use in food-producing species, withdrawal periods and residue depletion must be established under Regulation (EU) 2019/6 and the relevant maximum residue limits.